جۆری توێژینه‌وه‌: Original Article

نوسه‌ران

1 College of pharmacy, Mustansiriyah University, Baghdad.

2 Safeer Alimam Al-Hussain (A.S) Surgical Hospital,Karbala.

3 Institute of medical Technology, Baghdad, Iraq.

پوخته‌

The decrement of 25-hydroxy-vitamin D [25-ΟΗ-D] concentrations has
been increase the severity of cardiovascular disease especially in diabetic patients.
The aim of the present study was to assess the effect of atorvastatin on 25-OH-D
concentration in diabetic patients with hypercholesterolemia. Methods and patients:
Forty diabetic patients with hypercholesterolemia were participated in this work. For
comparison, thirty healthy subjects were inserted in the present study. Serum vitamin
D levels and lipid profile (total cholesterol, triglyceride, HDL, LDL and VLDL) were
measured. Results: Vitamin D levels significantly decrease ( p˂0.05) in diabetic
patients group (22.4±5.1 ng/ml) when compared to healthy group (32.44±4.12 ng/ml)
.After 8 weeks from taking atorvastatin (20 mg/day) the mean of serum vitamin D
were a slightly increase(26.4± 5.6) but not significant. Total cholesterol significantly
decreases after therapy. Conclusion: Vitamin D levels significantly decrease in
diabetic patients when compared to healthy subjects. There was no significant
difference in vitamin D patients before and after lipid lowering therapy.

وشه‌ بنچینه‌ییه‌كان

1. Ahmed Abbas, John Milles and  Sudarshan Ramachandran . Rosuvastatin and
Atorvastatin: Comparative Effects on Glucose Metabolism in Non-Diabetic

Patients with Dyslipidaemia. Clin Med Insights Endocrinol Diabetes. 2012; 5:
13–30.
2. Akio Nakashima,  Keitaro Yokoyama , Takashi Yokoo, and  Mitsuyoshi
Urashima . Role of vitamin D in diabetes mellitus and chronic kidney disease.
World J Diabetes. 2016 Mar 10; 7(5): 89–100.
3. Alvarez JA, Ashraf A: Role of vitamin D in insulin secretion and insulin
sensitivity for glucose Homeostasis. Int J Endocrinal. 2010, 2010: 351-385.
4. Benjamin M Leon and Thomas M Maddox. Diabetes and cardiovascular
disease: Epidemiology, biological mechanisms, treatment recommendations
and future research. World J Diabetes. 2015 Oct 10; 6(13): 1246–1258.
5. Bourlon PM, Billaudel B, Faure-Dussert A: Influence of vitamin D3 deficiency
and 1,25 dihydroxyvitamin D3 on de novo insulin biosynthesis in the islets of
the rat endocrine pancreas. J Endocrinol 1999, 160:87–95 .
6. Daria M. Adamczak. The Role of Toll-Like Receptors and Vitamin D in
Cardiovascular Diseases—A Review. Int. J. Mol. Sci. 2017,18,2252.
7. Floriana Elvira Ionică, Cătălina Pisoschi , Simona Negreş4 , Rigas F. Nikos5 ,
Mihai Tărâţă3 , Florica Popescu. Atorvastatin Influence on Glycemic Control
in Patients with Type 2 Diabetes Mellitus. FARMACIA, 2010, Vol. 58, 6: 728-
734.
8. Kayama Y,  Raaz U , Jagger A, Adam M,  Schellinger IN , Sakamoto M, Suzuki
H, Toyama K, Spin JM, Tsao PS. Diabetic Cardiovascular Disease Induced by
Oxidative Stress. Int J Mol Sci. 2015 Oct 23;16(10):25234-63. 
9. Manjunath G. Raju; Ajay Pachika; Sujeeth R. Punnam; Joseph C. Gardiner;
Mehdi H. Shishehbo; Samir R. Kapadia; George S. Abela . Statin Therapy in
the Reduction of Cardiovascular Events in Patients Undergoing Intermediate-
Risk Noncardiac, Nonvascular Surgery. Clin. Cardiol.2013, 36, 8, 456–461.
10. Matthias Wacker and Michael F. Holick . Sunlight and Vitamin D.
Dermatoendocrinol. 2013 Jan 1; 5(1): 51–108.

11. Mattila Mannisto . Vitamin D as a common supplement for insulin resistance
patients. Med Hypotheses. 2018, 78 (2): 123-128.
12. Rose Gilbertab , Ahmed Al-Janabiab, Oren Tomkins-Netzerab,and Sue
Lightmanab. Statins as anti-inflammatory agents: A potential therapeutic role
in sight-threatening non-infectious uveitis. Porto Biomedical Journal. Volume
2, Issue 2, March–April 2017, Pages 33-39
13. Teresa Martin. Vitamin D and Diabetes. Diabetes Spectrum 2011
May; 24(2): 113-118. 
14. Ulrich Laufs, Hubert Scharnagl,  Martin Halle, Eberhard Windler, Matthias
Endres, and Winfried März. Treatment Options for Statin-Associated Muscle
Symptoms. Dtsch Arztebl Int. 2015 Oct; 112(44): 748–755.